Enlivex Therapeutics Ltd.
Tel Aviv Stock Exchange ENLV.TA
Enlivex Therapeutics Ltd. Net Income Margin for the year ending December 31, 2023
Enlivex Therapeutics Ltd. Net Income Margin is NA for the year ending December 31, 2023. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.
Key data
| Date | Net Income Margin | EBITDA Margin | EBIT Margin | EBITDA |
|---|
Market news
Loading...
Don’t Miss A Beat
Tel Aviv Stock Exchange: ENLV.TA
| CEO | Dr. Oren Hershkovitz Ph.D. |
| IPO Date | July 22, 2019 |
| Location | Israel |
| Headquarters | 14 Einstein Street |
| Employees | 77 |
| Sector | Healthcare |
| Industries | |
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Key trends
Past 5 years
StockViz Staff
February 6, 2025
Any question? Send us an email